IP 1184. ZX008 (Fenfluramine) in Dravet’s Syndrome: First Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

¹ Bethel Epilepsy Centre, Paediatric Epileptology, Bielefeld, Germany

² Section of Pediatric Neurology, Department of Development and Regeneration, University Hospitals Gasthuisberg, Leuven, Belgium

³ UCSF School of Medicine, Los Angeles, United States

⁴ Department of Neuropediatrics, University Hospital, Jena, Germany

⁵ Epilepsie-Zentrum Bethel, Krankenhaus Mara, Kinderepileptologie, Bielefeld, Germany

⁶ Department of Neuropediatrics, Epilepsy Center, University Medical Center Freiburg, Freiburg, Germany

⁷ Schön-Klinik Vogtareuth, Hospital for Neuropediatrics and Neurological Rehabilitation, Vogtareuth, Germany

⁹ Kleinwachau - Saxonian Epilepsy Centre, Radeberg, Germany

¹⁰ DRK- Hospitals Berlin-Westend, Berlin, Germany

⁷ Schön-Klinik Vogtareuth, Hospital for Neuropediatrics and Neurological Rehabilitation, Vogtareuth, Germany

¹¹ Department of Neuropediatrics, University Children’s Hospital, University Hospitals Schleswig-Holstein, Kiel, Germany

¹² Department of Pediatric Neurology and Developmental Medicine, University Children’s Hospital, Tübingen, Germany

¹³ Zogenix Inc., Emeryville, California, United States

¹³ Zogenix Inc., Emeryville, California, United States

¹³ Zogenix Inc., Emeryville, California, United States

¹³ Zogenix Inc., Emeryville, California, United States

¹⁴ Zogenix International Ltd, Maidenhead, Berkshire, United Kingdom

¹³ Zogenix Inc., Emeryville, California, United States

¹⁵ Department of Neurology-Pediatric Neurology, Antwerp University Hospital, Antwerpen, Belgium